The trial is tied to a post-marketing commitment that FDA Commissioner Martin Makary put in place last year for all approved COVID vaccines.
By Bhanvi Satija LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech have halted recruitment for a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying ...
COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver relevant post-marketing data. Moderna is apparently also facing enrollment ...
Find the latest pfizer vaccine news from Fast company. See related business and technology articles, photos, slideshows and ...
Vaccine maker's critics hope for new attorney general to reverse Pam Bondi's hostility to clinical trial whistleblower's ...
The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...
The German biotechnology company currently employs 85 people at its manufacturing plant in Tuas.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results